Skipping Flu Shots May Up Dementia Risk by 60%
By
Simon Spichak, MSc
| July 18th, 2022
In a study of nearly 2 million people — the largest such study to date — researchers found more evidence that flu shots help…
Lab-Grown Mini-Brains Could Help Find Treatments for Alzheimer’s and Other Diseases
By
Étienne Aumont
| July 8th, 2022
Better Alzheimer’s treatments are going to require better models of Alzheimer’s brains in the lab, researchers say. Psychology researcher Étienne Aumont at the University…
FDA Fast-Tracks Alzheimer’s Drug Lecanemab; Decision Expected By Early 2023
By
Simon Spichak, MSc
| July 7th, 2022
Biogen and Eisai’s next disease-modifying Alzheimer’s drug candidate, lecanemab, has been granted FDA priority review, signaling that a decision could be made by early…
Does Early-Onset Alzheimer’s Progress Faster Than Later Onset?
By
Jessica Farthing
| July 6th, 2022
An early-onset Alzheimer’s diagnosis unleashes a landslide of questions: What is early-onset Alzheimer’s disease, what are its symptoms, and how does it differ from…
Study: Sleep Quality One Night Affects Dementia Symptoms the Next
By
Sara Balouch and Derk-Jan Dijk
| July 1st, 2022
Researchers discusses the ways in which people’s quality of sleep may influence their daily symptoms of Alzheimer’s. We’ve probably all experienced how a poor…
This Emory Alzheimer’s Researcher Is Working To Boost Diversity in Research
By
Alejandra O’Connell-Domenech
| June 30th, 2022
The importance of good clinical research and good clinical care is greater than one might think. Emory University Alzheimer’s researcher Dr. Monica Parker shares…
For Alzheimer’s Agitation, Promising Data from Rexulti
By
Being Patient
| June 29th, 2022
Rexulti (brexpiprazole) shares positive trial results for treating agitation in Alzheimer’s. Following this a bumpy road for another Alzheimer’s drug candidate that could supplant…
After 9 Years in Trials, Roche’s Crenezumab Stalls Out
By
Simon Spichak, MSc
| June 28th, 2022
The clinical trial failed to show that experimental Alzheimer’s drug crenezumab could prevent cognitive decline. Why the drug failed remains unclear. There were more…
More Aduhelm Drama: Packaging Could Waste Medicare Millions; Trial Tossed
By
Simon Spichak, MSc
| June 27th, 2022
New findings reveal that the way Aduhelm is packaged leads to wasted medication — and as much as $605 million per year of Medicare…
Alzheimer’s Drug Made of Bone Marrow Moves Through Trials
By
Nicholas Chan
| June 24th, 2022
Longeveron’s investigational early-stage Alzheimer’s drug Lomecel-B, made from donated bone marrow, is enrolling participants for a clinical trial. Scientists have faced obstacle after obstacle…
The Relationship Between Diabetes and Dementia
By
Simon Spichak, MSc
| June 21st, 2022
Here’s a primer on how diabetes is connected to dementia risk, and what you can do to reduce your chances of developing the two…
In Alzheimer’s and TBI, Exploring the Brain’s ‘White Matter’
By
Christopher Filley
| June 20th, 2022
You’ve likely heard of the brain’s gray matter. Here’s why the white matter is important, too. Neurology and psychiatry professor Christopher Filley at the…
Shonda Bell: Why Caregiving is a ‘Challenge’ and an ‘Honor’
By
Simon Spichak, MSc
| June 15th, 2022
Shonda Bell became an advocate for people with dementia after both of her parents were diagnosed with Alzheimer’s two years apart, requiring her to…
Quebec Bill Would Enable Medical Aid in Dying for Alzheimer’s
By
Simon Spichak, MSc
| June 13th, 2022
While medical aid in dying helps people in Canada die with dignity, to date, it excludes people living with dementia who cannot provide consent…
THC, CBD, & CBN: Can Cannabis Protect the Brain From Alzheimer’s?
By
Nicholas Chan
| June 10th, 2022
Salk Institute Neurobiologist Zhibin Liang discusses the neuroprotective effects of a cannabis compound known as cannabinol, and the road ahead to validate and build…